CCR4 and lymphoma: Other notable agents include CCX872, a CCR2 antagonist for pancreatic cancer, and mogamulizumab (KW‐0761), an anti‐CCR4 mAb, which is in phase II trials for adult T‐cell leukemia/lymphoma [349].